GlassScriptPhysician profile
Daniel Loren Faaborg
NPI 1265724470
$3,080.65
in general payments reported to CMS, 2019-2025
16 companies · $78.22 in 2025
The $78.22 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,375 · 2020: $1,051 · 2021: $146 · 2022: $220 · 2023: $108 · 2024: $103 · 2025: $78.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $289.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,021.54 | 2019-2025 | Lithovue, Axonics |
| Axonics, INC. | $564.06 | 2020-2023 | Axonics |
| Intuitive Surgical, INC. | $115.14 | 2019 | |
| Baxter Healthcare | $73.19 | 2023-2025 | Perclot, Tisseel |
| Endo Pharmaceuticals INC. | $70.25 | 2019 | |
| Allergan, INC. | $59.99 | 2019 | |
| Coloplast Corp | $42.20 | 2023-2024 | Altis |
| Astellas Pharma US INC | $24.81 | 2024 | Xtandi |
| Laborie Medical Technologies Corp. | $21.19 | 2023 | |
| Olympus America INC. | $16.73 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.69 | 2019 | |
| 180 Medical, INC. | $16.56 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.24 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.67 | 2019 | |
| Travere Therapeutics, INC. | $7.64 | 2020-2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $3.75 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Faaborg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.